scholarly journals Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer

2011 ◽  
Vol 6 (4) ◽  
pp. 781-785 ◽  
Author(s):  
Neal Ready ◽  
Nina A. Karaseva ◽  
Sergey V. Orlov ◽  
Alexander V. Luft ◽  
Olexandr Popovych ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)

Cancer ◽  
2018 ◽  
Vol 124 (24) ◽  
pp. 4667-4675 ◽  
Author(s):  
Daniel Morgensztern ◽  
Manuel Cobo ◽  
Santiago Ponce Aix ◽  
Pieter E. Postmus ◽  
Conrad R. Lewanski ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Line Treatment ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Phase 2 Study ◽  
Randomized Phase 2

scholarly journals OA05.05 Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)

2017 ◽  
Vol 12 (1) ◽  
pp. S261-S262 ◽  
Author(s):  
Taofeek Owonikoko ◽  
Kristiaan Nackaerts ◽  
Tibor Csoszi ◽  
Gyula Ostoros ◽  
Christina Baik ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Small Cell ◽  
Second Line ◽  
Phase 2 ◽  
Small Cell Lung ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Phase 2 Study ◽  
Randomized Phase 2
Sign in / Sign up

Export Citation Format

Share Document